Francesco Massari, Veronica Mollica, Ondrej Fiala, Ugo De Giorgi, Jakub Kucharz, Maria Giuseppa Vitale, Javier Molina-Cerrillo, Gaetano Facchini, Emmanuel Seront, Edoardo Lenci, Maria T Bourlon, Francesco Carrozza, Renate Pichler, Cristian Lolli, Zin W Myint, Ravindran Kanesvaran, Mariangela Torniai, Pasquale Rescigno, Alfonso Gomez de Liaño, Roubini Zakopoulou, Sebastiano Buti, Camillo Porta, Enrique Grande, Matteo Santoni
BACKGROUND AND OBJECTIVE: Papillary renal cell carcinoma (pRCC) is the most frequent histological subtype of non-clear cell RCC (nccRCC). Owing to the heterogeneity of nccRCC, patients are often excluded from large phase 3 trials focused on clear cell RCC, so treatment options for nccRCC remain limited. Our aim was to investigate the efficacy of first-line treatment with tyrosine kinase inhibitors (TKIs) or immuno-oncology (IO)-based combinations in patients with pRCC. METHODS: We performed a multicenter retrospective analysis of real-world data collected for patients with advanced pRCC treated in 40 centers in 12 countries as part of the ARON-1 project (NCT05287464)...
April 3, 2024: European Urology Oncology